FDA approves antiretroviral drug

Aug 07, 2007

The U.S. Food and Drug Administration has approved the antiretroviral drug maraviroc for use in adult human immunodeficiency virus patients.

The FDA said maraviroc, sold under the trade name Selzentry, is the first in a new class of drugs designed to slow the advancement of HIV.

Maraviroc is approved for use in combination with other antiretroviral drugs for the treatment of adults with CCR5-tropic HIV-1, who have been treated with other HIV medications and who have evidence of elevated levels of HIV in their blood, the FDA said.

Rather than fighting HIV inside white blood cells, maraviroc prevents the virus from entering uninfected cells by blocking the predominant route of entry -- the CCR5 co-receptor. CCR5 is a protein on the surface of some types of immune cells.

"This is an important new product for many HIV-infected patients who have not responded to other treatments and have few options," said Dr. Steven Galson, director of the FDA's Center for Drug Evaluation and Research.

The product label includes a boxed warning about liver toxicity -- hepatoxicity -- and a statement about the possibility of heart attacks.

Maraviroc is distributed by Pfizer Inc.

Copyright 2007 by United Press International

Explore further: Italy bans Novartis flu vaccine after suspicious deaths

add to favorites email to friend print save as pdf

Related Stories

HIV drug maraviroc effective for drug-resistant patients

Oct 01, 2008

As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death. Now, maraviroc, the first of a new class of HIV drugs called CCR5 receptor antagonists, ...

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.